Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2124156
Abstract: ABSTRACT Introduction Diffuse large B-cell lymphoma (DLBCL) is not a single entity but instead represents a collection of interrelated malignancies having distinct molecular features. Recent multiomics studies have independently identified the presence of at least… read more here.
Keywords: cell lymphoma; large cell; diffuse large; upfront therapy ... See more keywords
MP37-10 ASSOCIATION OF TUMOR BURDEN WITH THE ELIGIBILITY OF UPFRONT THERAPY IN PATIENTS WITH CASTRATION NAIVE PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000886.010
Abstract: INTRODUCTION AND OBJECTIVE:Although several large-scale studies reported a robust benefit of upfront therapy for mHNPC, not all patients with mHNPC experienced mCRPC progression. As there is a conc... read more here.
Keywords: therapy; burden eligibility; upfront therapy; mp37 association ... See more keywords